Novel Lipid Inhibitors of TLR Effective at Reducing RSV and Influenza A Infection In Vivo
Four novel compounds are undergoing a toxicology study with a mouse model of RSV infection.
Respiratory Syncytial Virus (RSV), influenza A virus, rhinovirus, sepsis-induced ARDS, asthma, reducing the effects of inflammation during mechanical ventilation, chronic bronchitis, COPD, cystic fibrosis, idiopathic pulmonary fibrosis.
Respiratory Syncytial Virus (RSV) is the most common cause of hospitalization for respiratory illness in young children and 90% of children under the age of 2 will be infected by this virus. RSV infection and associated inflammation have also been shown to be a substantial contributing factor in the exacerbation of chronic lung diseases in adults and the elderly. Influenza A virus (IAV) is a worldwide public health problem causing 500,000 deaths each year with the highest death rates among newborns, the elderly and adults with chronic lung diseases.
Patent Number: US20080242640A1
Application Number: US200857967A
Inventor: Voelker, Dennis R.
Priority Date: 29 Mar 2007
Priority Number: US20080242640A1
Application Date: 28 Mar 2008
Publication Date: 2 Oct 2008
IPC Current: A61K003166 | A61K0031683
US Class: 514120 | 514130
Assignee Applicant: National Jewish Medical and Research Centernver
Title: Surfactant Lipids, Compositions Thereof and Uses Thereof
Usefulness: Surfactant Lipids, Compositions Thereof and Uses Thereof
Summary: The method is useful to inhibit inflammation or pathogen infection, preferably viral infection comprising respiratory syncytial virus infection to the individual, where the inflammation or pathogen infection is associated with a toll-like receptor (TLR) comprising TLR1 (preferred), TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR10; and the individual is a neonatal infant, who has: an infection, condition or disease associated with TLR2 comprising cytomegalovirus infection, herpes simplex virus infection, measles, a protozoan infection, a fungal infection, and Varicella zoster infection; an infection, condition or disease associated with TLR3 comprising a viral infection and a cancer; an infection, condition or disease associated with TLR6 comprising a bacterial infection, a protozoan infection and a fungal infection; an infection, condition or disease associated with TLR7 comprising an autoimmune disease, a cancer, and a viral infection; an infection, condition or disease associated with TLR8 comprising autoimmune disease, basal cell carcinoma, Bowen's disease, condyloma, genital warts, human immunodeficiency virus (HIV), rhinovirus, parainfluenza virus, Human parechovirus, melanoma, and mollusca contagiosa; and a respiratory disorder comprising adult respiratory distress syndrome (ARDS), acute lung injury (ALI), viral infection associated with asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, tuberculosis, reactive airway disease syndrome, interstitial lung disease, rhinitis and parasitic lung disease, and the pathogen infection is human immunodeficiency virus infection, rhinovirus infection, parainfluenza virus infection, human parechorvirus infection, influenza infection, papilloma virus infection and Varicella zoster infection (all claimed).
Novelty: Inhibiting inflammation/pathogen infection, preferably viral infection, comprises administering anionic lipid/related compound, which has hydrophobic portion, negatively charged portion and uncharged, polar portion
診斷/治療
人類免疫缺陷病毒
美國
